Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals

Rilpivirine (RPV), the latest nonnucleoside reverse transcriptase inhibitor active against HIV-1, is prescribed in a standard dosage of 25 mg once a day in combination with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). The aim of this observational study was to characterize the RPV ph...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Aouri, Manel, Barcelo, Catalina, Guidi, Monia, Rotger, Margalida, Cavassini, Matthias, Hizrel, Cédric, Buclin, Thierry, Decosterd, Laurent A., Csajka, Chantal
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2016
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5192124/
https://ncbi.nlm.nih.gov/pubmed/27799217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00899-16
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares